Severe Asthma Abstracts From 2020 AAAAI Annual Meeting

Michael Wechsler, MD


April 13, 2020

Due to ongoing concerns about coronavirus, the 2020 annual meeting of the American Academy of Allergy, Asthma & Immunology, to be held in Philadelphia, was canceled. The meeting abstracts were made available online, however.

Dr Michael Wechsler reviewed several important findings relating to the treatment of severe asthma.

The Liberty Asthma QUEST Study demonstrated that in patients with uncontrolled moderate to severe asthma, higher baseline nitric-oxide levels were associated with higher severe asthma exacerbation rates. Risk was particularly high in patients also having blood eosinophil counts greater than 300 cells.

In another study, dupilumab showed consistent efficacy in patients with difficult-to-treat type 2 inflammation as defined by the GINA cutoffs for type 2 inflammatory biomarkers.

Wechsler and his colleagues led a study that monitored patients for 6 months before and after treatment with reslizumab. The findings suggest that a need for symptom relief is an important driver of use of biologics in clinical practice. Symptomatic improvements appeared to be associated with significant healthcare utilization reduction among patients receiving reslizumab.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.